Full video transcriptClick to expand
Auto-generated transcript of @realdrbae's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00Beware of ozopic babies.
- 0:02There was a recent article that came out
- 0:04said that you might have an increased risk of getting
- 0:06pregnant if you're on ozopic.
- 0:08The reason for that is as follows.
- 0:10Ozopic, or this class of medications,
- 0:12helps you lose weight through delayed gastric emptying,
- 0:14meaning food moves more slowly from the stomach to the intestines.
- 0:16You feel more full, you eat less, you lose weight.
- 0:19But that delayed gastric emptying can also
- 0:21affect how well absorbed your oral contraceptive pill is.
- 0:25So if it doesn't get absorbed, your ability to get pregnant
- 0:27may be higher.
- 0:29So if you just had a baby, you're trying to lose the baby
- 0:31weight, be aware that it is possible you have an increased
- 0:33risk of getting pregnant.
- 0:34But keep in mind also, this is not new.
- 0:37When they submitted the paperwork to the FDA,
- 0:39ozopic will go away there or aware that this was a possibility.
Does Ozempic actually make birth control less effective?
Quick answer
Semaglutide's effects on gastric emptying have been shown to reduce peak plasma concentrations of ethinylestradiol and levonorgestrel in oral contraceptives, prompting an FDA label warning recommending non-oral or barrier contraception for four weeks after initiation and each dose increase. Postpartum patients using GLP-1 drugs for weight loss face a compounded risk because weight loss itself can restore ovulation in people with obesity-related anovulation, a mechanism distinct from the drug-pill absorption interaction the video describes. Clinicians should discuss contraceptive method selection proactively with any patient initiating GLP-1 therapy who is of reproductive age and not seeking pregnancy.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Semaglutide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 7 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Does Ozempic actually make birth control less effective?, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Claim path
Keep researching this semaglutide video claims cluster
Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "Does Ozempic actually make birth control less effective?" from Jonathan Kaplan. We read the clip as a GLP-1 social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Semaglutide's effects on gastric emptying have been shown to reduce peak plasma concentrations of ethinylestradiol and levonorgestrel in oral contraceptives, prompting an FDA label warning recommending non-oral or barrier contraception for four weeks after initiation and each dose increase.
The reason this review is not generic is the source wording and the canonical claim label "glp1 birth control and ozempic use caution healthline." In this clip, the useful excerpt is: "Beware of ozopic babies." That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.
The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
Semaglutide's effects on gastric emptying have been shown to reduce peak plasma concentrations of ethinylestradiol and levonorgestrel in oral contraceptives, prompting an FDA label warning recommending non-oral or barrier contraception for four weeks after initiation and each dose increase.
FormBlends verdict
Compounded Semaglutide safety, access, evidence, and fit
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Semaglutide's effects on gastric emptying have been shown to reduce peak plasma concentrations of ethinylestradiol and levonorgestrel in oral contraceptives, prompting an FDA label warning recommending non-oral or barrier contraception for four weeks after initiation and each dose increase. Postpartum patients using GLP-1 drugs for weight loss face a compounded risk because weight loss itself can restore ovulation in people with obesity-related anovulation, a mechanism distinct from the drug-pill absorption interaction the video describes. Clinicians should discuss contraceptive method selection proactively with any patient initiating GLP-1 therapy who is of reproductive age and not seeking pregnancy.
- The FDA prescribing label for semaglutide recommends non-oral or barrier contraception for 4 weeks after starting the drug and after each dose increase.
- Marbury et al. (2021, Clinical Pharmacokinetics) found semaglutide reduced peak ethinylestradiol levels by roughly 22% and levonorgestrel by roughly 20%, though total drug exposure was less affected.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.
Review Compounded SemaglutideWhat You'll Learn
- The FDA prescribing label for semaglutide recommends non-oral or barrier contraception for 4 weeks after starting the drug and after each dose increase.
- Marbury et al. (2021, Clinical Pharmacokinetics) found semaglutide reduced peak ethinylestradiol levels by roughly 22% and levonorgestrel by roughly 20%, though total drug exposure was less affected.
- IUDs, hormonal implants, patches, vaginal rings, and injectable contraceptives are not affected by gastric emptying changes and are reliable options for people on GLP-1 drugs.
- Weight loss restoring ovulation in people with obesity-related anovulation may be a larger contributor to unintended pregnancy on GLP-1 drugs than the drug-pill absorption interaction.
- The creator is correct that this risk was flagged in original FDA documentation, not a new discovery from a single news article.
- Delayed gastric emptying is not the primary mechanism of weight loss on semaglutide. Central appetite suppression is the main driver, according to Drucker (2018, Cell Metabolism).
- Anyone of reproductive age starting a GLP-1 drug should discuss contraceptive options with their prescriber before or at the time of initiation.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @realdrbae actually say?
The creator warned viewers about what they called "ozopic babies," claiming that semaglutide and similar GLP-1 drugs may reduce the effectiveness of oral contraceptive pills. The mechanism they offered: delayed gastric emptying slows how quickly food moves from stomach to intestines, and that same slowing could impair how well the pill gets absorbed. They added that this risk was disclosed to the FDA during the drug's approval process, which is actually accurate and worth noting.
The warning was directed specifically at postpartum people trying to lose baby weight, which is a real use case given how semaglutide has grown in popularity for weight loss. The core claim is medically plausible. The question is whether the evidence actually supports the level of concern being raised here.
Does the science back this up?
Partially, yes. But the picture is more complicated than the video lets on. Novo Nordisk's own prescribing information for semaglutide does include a warning that oral contraceptives may be affected, recommending patients switch to a non-oral method or add a barrier method for four weeks after starting the drug and after each dose increase.
A pharmacokinetic sub-study by Marbury et al. (2021, Clinical Pharmacokinetics) found that semaglutide reduced peak concentration (Cmax) of ethinylestradiol by about 22% and of levonorgestrel by about 20%. Those are real reductions. However, overall drug exposure (AUC) was not significantly altered. What that means clinically is still debated. Lower peak levels do not automatically translate to contraceptive failure, but the signal was enough for regulators to act. The FDA label is not just boilerplate caution.
What did they get wrong (or right)?
The delayed gastric emptying explanation is directionally right but oversimplified. GLP-1 drugs slow gastric emptying, which can reduce peak absorption of oral drugs taken at the same time. The creator frames this as pills literally not getting absorbed, which overstates it. The pills still absorb. The timing and peak levels shift, which is a meaningful pharmacokinetic difference but not the same as the medication simply failing to work.
The claim that this is "not new" and was flagged with the FDA paperwork is accurate. The prescribing information for Ozempic has carried this language since approval. Credit where it's due: that's a responsible thing to include.
What the video skips entirely is that this concern applies more to semaglutide and liraglutide than to tirzepatide, which has less pronounced effects on gastric emptying in some studies. It also doesn't mention that IUDs, implants, patches, and injections are completely unaffected by this mechanism, which would have been genuinely useful information.
What should you actually know?
If you are on an oral contraceptive and starting any GLP-1 drug, the FDA-approved prescribing information recommends using a non-oral or barrier method of contraception for four weeks after initiation and after each dose escalation. This is not a fringe recommendation from one worried physician. It is in the label.
Postpartum patients face a specific compounding risk: fertility can return quickly after delivery, GLP-1 use for postpartum weight loss is increasing, and oral contraceptives are commonly prescribed in that period. The intersection matters.
The "ozempic baby" phenomenon reported anecdotally in media coverage likely also involves a separate mechanism: weight loss itself can restore ovulation in people with obesity-related anovulation, independent of any drug-pill interaction. The video does not address this at all, and it may actually be the bigger contributor to unintended pregnancy in this population.
- Switch to a non-oral contraceptive method or add a barrier method when starting a GLP-1 drug
- This recommendation applies for four weeks after starting and after every dose increase
- IUDs, implants, patches, rings, and injections are not affected by gastric emptying changes
- Weight loss restoring ovulation is a separate and potentially larger risk factor for unintended pregnancy
- Talk to your prescriber before making any changes to your contraceptive plan
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Jonathan Kaplan · TikTok creator
2.7M views on this video
Birth control and Ozempic… use caution 🫡 @Healthline
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about the fda prescribing label for semaglutide recommends non-oral?
The FDA prescribing label for semaglutide recommends non-oral or barrier contraception for 4 weeks after starting the drug and after each dose increase.
What does the video say about marbury et al. (2021, clinical pharmacokinetics) found semaglutide reduced peak?
Marbury et al. (2021, Clinical Pharmacokinetics) found semaglutide reduced peak ethinylestradiol levels by roughly 22% and levonorgestrel by roughly 20%, though total drug exposure was less affected.
What does the video say about iuds, hormonal implants, patches, vaginal rings,?
IUDs, hormonal implants, patches, vaginal rings, and injectable contraceptives are not affected by gastric emptying changes and are reliable options for people on GLP-1 drugs.
What does the video say about weight loss restoring ovulation in people with obesity-related anovulation may?
Weight loss restoring ovulation in people with obesity-related anovulation may be a larger contributor to unintended pregnancy on GLP-1 drugs than the drug-pill absorption interaction.
What does the video say about the creator?
The creator is correct that this risk was flagged in original FDA documentation, not a new discovery from a single news article.
What does the video say about delayed gastric emptying?
Delayed gastric emptying is not the primary mechanism of weight loss on semaglutide. Central appetite suppression is the main driver, according to Drucker (2018, Cell Metabolism).
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Jonathan Kaplan, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.